CHELSI CLAYTON: Open Payments
NPI 1760974711 · VIDOR, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 82 payments from 19 companies in 2025. Trend: 2023 $1,431 · 2024 $1,198 · 2025 $1,329
Food & beverage: $1,329
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $232 |
| ABBVIE INC. | 16 | $222 |
| Amgen Inc. | 18 | $146 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Neurocrine BioSciences, Inc. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| Novo Nordisk Inc | 4 | $68 |
| PFIZER INC. | 3 | $58 |
| Exact Sciences Corporation | 2 | $39 |
Products named: FARXIGA, VRAYLAR, OTEZLA, Kerendia, TRINTELLIX, INGREZZA, CAPLYTA, QULIPTA.
Industry payments across TX — which companies pay providers there.
